MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income (loss)
-$9,491K
(-101.83%↓ Y/Y)
Supply Sales
$32,642K
Nuvaxovid Sales
$9,558K
Income (loss) before
income tax expense
-$8,506K
(-101.64%↓ Y/Y)
Income tax expense
$985K
(-17.92%↓ Y/Y)
Other income, net
$11,825K
(17.59%↑ Y/Y)
Licensing Royalties And
Other
$97,314K
Product
$42,200K
Income (loss) from
operations
-$15,430K
(-102.99%↓ Y/Y)
Total revenue
$139,514K
(-79.07%↓ Y/Y)
Interest expense
$4,901K
(-14.36%↓ Y/Y)
Total expenses
$154,944K
(2.52%↑ Y/Y)
Research and development
$95,472K
(7.35%↑ Y/Y)
Cost of sales
$30,695K
(117.46%↑ Y/Y)
Selling, general, and
administrative
$28,777K
(-40.16%↓ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
NOVAVAX INC (NVAX)
NOVAVAX INC (NVAX)